|
|
Article: Allergan and Kyorin Pharmaceutical Co., Ltd. Sign Exclusive Licensing Agreement to Develop and Market ALPHAGAN-R-/ ALPHAGAN-R- P in Japan.
- Article from:
- Business Wire
- Article date:
- May 26, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
IRVINE, Calif.--(BUSINESS WIRE)--May 26, 2004
Allergan, Inc. (NYSE:AGN) today announced that it has entered into an exclusive licensing agreement with Kyorin Pharmaceutical, Co., Ltd. (Kyorin) in Japan to develop and market the ALPHAGAN(R)/ ALPHAGAN(R) P Franchise (Brimonidine Tartrate solution 0.2 percent and Brimonidine Tartrate Purite solution 0.15 percent) within the ophthalmic specialty area. The ALPHAGAN(R) Franchise represents the third largest selling glaucoma franchise in the world as measured by 2003 revenue, according to IMS Health Inc. In 2003, global sales for the ALPHAGAN(R) Franchise were $287 ...
Related newspaper, magazine, and journal articles:
|
|
Article: Kyorin Pharmaceutical, Novartis AG Enter into ...
JCNN News Summaries - Japan Corporate News Network;
February 17, 2006 ;
355 words
...Tokyo, Feb 17, 2006 - (JCN) - Kyorin Pharmaceutical announced on February 16 that it has signed a licensing ... keeps a worldwide exclusive right to KRP-203. Kyorin Pharmaceutical announced on February 16 that it has signed a licensing ...
|
|